What’s in a Name? ChemSpider ID

What’s in a Name? ChemSpider ID

The naming of drugs is a curious matter.

My husband had an unconventional friend who let his cat pick his first kid’s name. He wrote down the options on pieces of paper, crumpled them up, and set them down in front of the cat. There was a finish line, and the first ball of paper to be batted across it won.

Consider Filspari™, Jaypirca™, Jesduvroq, and Orserdu™. My husband and I watch the news at night and are astonished at the fanciful and preposterous names of medications. This is a sampling of new drugs coming to market in 2023. We often wonder if the pharmaceutical companies let their cats devise the names of the meds.

Why am I bringing this up? Because in preparation for the ICD-10 Coordination and Maintenance Committee Meeting that was being held March 7 and 8, 2023, I reviewed the agendas. The first day was PCS (Procedure Coding System) day, and the second day was for ICD-10-CM diagnosis codes (although sometimes we start that on day one if we finish procedures early). The PCS had a list of new technology add-on payment (NTAP) procedure codes involving the administration of a therapeutic agent. They announced ahead of time that they planned to not discuss them during the meeting, but made them available in advance to review. Examples were administration of Glofitamab, Posoleucel, Rezafungin, and Quizartinib.

Drugs basically have three names (for you Broadway-philes, this reminds me of Andrew Lloyd Webber’s Cats): their chemical compound name, their generic name, and their brand name. The chemical name describing the actual molecular formula is often quite complex, and too cumbersome to be utilized in common use, and so a shorthand code name may be given. There are also databases that aggregate and categorize chemical compounds, such as ChemSpider ID.

The generic or non-proprietary name is intended to standardize drug identification globally, and is applied to the active ingredient of the drug. The United States Adopted Names (USAN) Council and the World Health Organization (WHO) International Nonproprietary Names (INN) must approve the generic name. The ending, or suffix, tells us what family a drug is from and can give information about its mechanism of action. For instance, “-mab” indicates monoclonal antibodies, “-pril” identifies an angiotensin converting enzyme (ACE) inhibitor, and “-olol” signifies a beta blocker. There are more than 600 stems and sub-stems that identify classes of drugs.

Some letters are avoided (H, K, J, W, and Y) because they have no analogs in certain languages. They can’t use the company’s name within the drug’s name and have to avoid promotional terms like “best” or “strongest.” They also avoid medical terminology, because they don’t want to limit the drug to a specific indication. For instance, they wouldn’t use “Onc-“ or “Uro-“ at the beginning of the generic name.

When they have a small set of contenders, the drug company submits them to USAN for (hopefully) approval of one. Once the U.S. name has been selected, the process is repeated with the WHO. The name they accept is published on an international list for the public to review. When a period of time has elapsed, barring objection from the public, the new nonproprietary name is released.

Then the real fun begins! The manufacturer gets to invest time and money deriving a mellifluous brand name that will capture the public’s attention and elicit positive feelings about the medication. I like the example of IBRANCE® (Palbociclib), a breast cancer drug, which purportedly is an amalgamation of “inspiration, embrace, vibrancy.” Supposedly Viagra® came from “vigorous” (stream) and “Niagara.” Latisse®, the eyelash growth drug, is a merger of “lash” and “Matisse,” the artist.

Again, the name can’t make an overt claim or be promotional, and shouldn’t include generic name stems. But they often try to convey the action of the medication, like Lopressor®, which is an antihypertensive medication or Glucotrol®, which is meant to control glucose levels. Sometimes, the brand name is a shortened version of the generic name, like Keflex for cephalexin.

The brand name has to be unique and can’t be too similar to another medication such that it might cause a dispensing error. It can’t look or sound like another drug. They even check handwritten samples and have people with a variety of accents pronounce the proposed name. This is another reason why wacky letters may be found in the names in odd places, like Rinvoq® or Xeljanz®. Personally, I think they should be sure the drug is pronounceable by the average consumer, too. The drug company does market research to see what healthcare professionals and John Q. Everyman think.

After conjuring up many options and taking a great deal of time (up to four years!), only one proposed name will be assessed by the Food and Drug Administration (FDA) at a time, so the drug company picks their favorite. A total of 20-35 percent of medication names are rejected on the basis of safety considerations. If it is rejected, they have to try again.

And I suppose, if all else fails, they can always fall back on asking the cat to choose a different name to submit next.

Programming note: Listen to Dr. Erica Remer when she cohosts Talk Ten Tuesdays, Tuesday, 10 Eastern with Chuck Buck.

Facebook
Twitter
LinkedIn

Erica Remer, MD, FACEP, CCDS, ACPA-C

Erica Remer, MD, FACEP, CCDS, ACPA-C has a unique perspective as a practicing emergency physician for 25 years, with extensive coding, CDI, and ICD-10 expertise. As physician advisor for University Hospitals Health System in Cleveland, Ohio for four years, she trained 2,700 providers in ICD-10, closed hundreds of queries, fought numerous DRG clinical determination and medical necessity denials, and educated CDI specialists and healthcare providers with engaging, case-based presentations. She transitioned to independent consulting in July 2016. Dr. Remer is a member of the ICD10monitor editorial board and is the co-host on the popular Talk Ten Tuesdays weekly, live Internet radio broadcasts.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

Enhancing Outcomes with CDI-Coding-Quality Collaboration in Acute Care Hospitals

Enhancing Outcomes with CDI-Coding-Quality Collaboration in Acute Care Hospitals

Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.

November 21, 2024
Comprehensive Inpatient Clinical Documentation Integrity: From Foundations to Advanced Strategies

Comprehensive Outpatient Clinical Documentation Integrity: From Foundations to Advanced Strategies

Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.

September 5, 2024
Advanced Outpatient Clinical Documentation Integrity: Mastering Complex Narratives and Compliance

Advanced Outpatient Clinical Documentation Integrity: Mastering Complex Narratives and Compliance

Enhancing outpatient clinical documentation is crucial for maintaining accuracy, compliance, and proper reimbursement in today’s complex healthcare environment. This webcast, presented by industry expert Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, will provide you with actionable strategies to tackle complex challenges in outpatient documentation. You’ll learn how to craft detailed clinical narratives, utilize advanced EHR features, and implement accurate risk adjustment and HCC coding. The session also covers essential regulatory updates to keep your documentation practices compliant. Join us to gain the tools you need to improve documentation quality, support better patient care, and ensure financial integrity.

September 12, 2024

Trending News

Featured Webcasts

Patient Notifications and Rights: What You Need to Know

Patient Notifications and Rights: What You Need to Know

Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.

December 5, 2024
Navigating the No Surprises Act & Price Transparency: Essential Insights for Compliance

Navigating the No Surprises Act & Price Transparency: Essential Insights for Compliance

Healthcare organizations face complex regulatory requirements under the No Surprises Act and Price Transparency rules. These policies mandate extensive fee disclosures across settings, and confusion is widespread—many hospitals remain unaware they must post every contracted rate. Non-compliance could lead to costly penalties, financial loss, and legal risks.  Join David M. Glaser Esq. as he shows you how to navigate these regulations effectively.

November 19, 2024
Post Operative Pain Blocks: Guidelines, Documentation, and Billing to Protect Your Facility

Post Operative Pain Blocks: Guidelines, Documentation, and Billing to Protect Your Facility

Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.

October 24, 2024
The OIG Update: Targets and Tools to Stay in Compliance

The OIG Update: Targets and Tools to Stay in Compliance

During this RACmonitor webcast Dr. Ronald Hirsch spotlights the areas of the OIG’s Work Plan and the findings of their most recent audits that impact utilization review, case management, and audit staff. He also provides his common-sense interpretation of the prevailing regulations related to those target issues. You’ll walk away better equipped with strategies to put in place immediately to reduce your risk of paybacks, increased scrutiny, and criminal penalties.

September 19, 2024

Trending News

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24